6533b839fe1ef96bd12a69fe
RESEARCH PRODUCT
Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease
A OrlandoA ArmuzziC PapiVito AnneseS ArdizzoneL BianconeA BortoliF CastiglioneR D’inca'P GionchettiA KohnG PoggioliF RizzelloM VecchiMario Cottonesubject
Guidelines.Biologics.Inflammatory bowel disease.description
Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.
year | journal | country | edition | language |
---|---|---|---|---|
2011-01-01 |